z-logo
Premium
Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study
Author(s) -
Boada Mercè,
López Oscar L.,
Olazarán Javier,
Núñez Laura,
Pfeffer Michael,
Puente Orlando,
PiñolRipoll Gerard,
Gámez José E.,
Anaya Fernando,
Kiprov Dobri,
Alegret Montserrat,
Grifols Carlota,
Barceló Miquel,
Bozzo Jordi,
Szczepiorkowski Zbigniew M.,
Páez Antonio
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12477
Subject(s) - placebo , medicine , albumin , quality of life (healthcare) , neuropsychology , cohort , verbal fluency test , randomized controlled trial , alzheimer's disease , gastroenterology , disease , psychiatry , cognition , pathology , alternative medicine , nursing
Abstract Introduction We report the effects of plasma exchange (PE) with albumin replacement on neuropsychological, neuropsychiatric, and quality‐of‐life (QoL) outcomes in mild‐to‐moderate Alzheimer's disease (AD) patients in a phase 2b/3 trial (Alzheimer's Management by Albumin Replacement [AMBAR] study). Methods Three hundred forty‐seven patients were randomized into placebo (sham‐PE) and three PE‐treatment arms with low/high doses of albumin, with/without intravenous immunoglobulin (IVIG). Specific test measurements were performed at baseline; month 2 (weekly conventional PE); months 6, 9, and 12 (monthly low‐volume PE [LVPE]); and month 14. Results The PE‐treated mild‐AD cohort improved their language fluency and processing speed versus placebo at month 14 (effect sizes: >100%; P ‐values: .03 to .001). The moderate‐AD cohort significantly improved short‐term verbal memory (effect sizes: 94% to >100%; P ‐values: .02 to .003). The progression of the neuropsychiatric symptoms of PE‐treated was similar to placebo. Mild‐AD patients showed improved QoL ( P ‐values: .04 to .008). Discussion PE‐treated AD patients showed improvement in memory, language abilities, processing speed, and QoL‐AD. No worsening of their psychoaffective status was observed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here